Shannon A. Miller, Pharm.D., BCACP

Shannon A. Miller

Assistant Director of the Orlando Campus/Clinical Associate Professor

Pharmacotherapy and Translational Research

OFFICE: 6550 Sanger Road - Room 422, Orlando, FL 32827

EMAIL: smiller@cop.ufl.edu

PHONE: 407-313-7005

CV: Link to CV

 

EDUCATION

  • Pharm.D., University of Florida

BIOGRAPHICAL SKETCH

Dr. Miller comes to us from Florida Hospital where she was a Family Medicine Faculty member and Ambulatory Care Clinical Pharmacist for 17 years.  Dr. Miller received her PharmD degree from the University of Florida College of Pharmacy and completed a Primary Care Residency at Florida Hospital in Orlando, FL. After residency, she created a faculty position within the family medicine residency and started numerous clinics including anticoagulation, diabetes, hypertension and asthma. Dr. Miller worked closely with the family medicine residents and received Faculty of the Year in 2009 and 2010 Lecturer of the Year in 2002, and Outstanding Educator in 2000.  She has been active with the College, serving as a preceptor, a course facilitator on the Orlando campus, and as a member of the College’s National Advisory Board. She was named University of Florida preceptor of the year in 2001, 2003, and 2009.

AFFILIATIONS

American College of Clinical Pharmacy

Florida Pharmacy Association

American Pharmacists Association

American Society of Health-System Pharmacists

PUBLICATIONS

Clements E, Miller S, St Onge E. Sitagliptin and metformin as combination therapy in the treatment of type 2 diabetes, P and T.  2012;(37)699-708.

Miller SA, St Onge EL. Otelixizumab: A novel agent for the prevention of type 1 diabetes mellitus. Expert Opinion on Biological Therapy 2011 ;(11)11:1525-32.

Motycka CA, St. Onge EL, Miller SA.  Current treatment options for obesity and novel treatments on the horizon.  P&T, 2011; 36(5): 282-290.

Clayville L, Vogel Anderson K, Miller S, St. Onge E.  New options in anticoagulation for VTE and stroke prevention.  P&T 2011; 36(2): 86-99.

St. Onge E, Miller S, Vogel Anderson K.  Role of incretin therapies in the management of type 2 diabetes mellitus.  J of Clinical Metab and Diabetes 2010; 1(2): 1-11.

St. Onge E, Miller S.  GLP-1 analogs for the treatment of type 2 diabetes mellitus.  FSHP Report 2010; July: 8.

St. Onge EL, Miller SA. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. Expert Opin. Biol. Ther. 2010; 10(5):801-806.

Miller S, St. Onge EL, Accardi JR.  Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus.  Diabetes, Metabolic Syndrome, and Obesity 2009; 2:22-30.

St. Onge EL, Motycka CA, Miller SA.  Cardiovascular risk associated with medications used to treat type 2 diabetes mellitus.  P&T 2009;34(7):368-378.

St. Onge EL, Miller SA. “Targeting the incretin effect: a novel approach in the treatment of type 2 diabetes”. Journal of Pharmacy Practice 2009; 22(3): 320-332.

Miller SA, Accardi JR, St. Onge EL. “Angiotensin II vaccine: a novel approach in the treatment of hypertension” Expert Opin. Biol. Ther. November 2008; 8(11):1-5.

Miller SA, St. Onge EL, Taylor JR. “DPP-IV Inhibitors: a review of sitagliptin, vildagliptin, alogliptin, and saxagliptin”. Formulary 2008; 43 (4):122-134.

St. Onge EL, Miller SA.  ”Pain associated with diabetic peripheral neuropathy: a review of available treatments”.  P&T 2008; 33(3): 166-176.

Miller SA, Spruill T. “Physician communication when prescribing new meds”. Peer Reviewed. Family Medicine Digital Resource Library (fmdrl.org) 2007 October.

Miller SA, St. Onge, E.”Sitagliptin: a dipeptidyl peptidase inhibitor in the treatment of diabetes”. Annals of Pharmacotherapy. August 2006; 40 (7-8): 1336-43.

Miller SA, Warrick B. “Impact of Diabetes Education on Education on Clinical Measures”. Poster Presentation.  American Osteopathic Association National Meeting;  2003 October.

Miller SA, Warrick B. “Impact of Diabetes Education on Education on Clinical Measures”. Abstract. Journal of American  Osteopathic Association; 2003 August.

Simon, K; Miller, SA.  “Pain management at end of life”. Journal of American Osteopathic Association; 2001 October.